Abbvie Stock Outlook and Reported Financials, Celebrates 30th Annual Cystic Fibrosis Scholarship
For the two $25,000 scholarships, forty kids with cystic fibrosis (CF) are competing based on their academic achievement, inventiveness, and extracurricular activities. The scholarship program this year commemorates 30 years of AbbVie's (NYSE:ABBV) dedication to ... [Read]
Psilocybin and MDMA Get the Green Light for Medical Use in Canada
After facing legal scrutiny for decades, psychedelics including MDMA and psilocybin received a stamp of approval from Health Canada for medical purposes. Canada’s legislation now permits the use of psychedelics beyond palliative care, something health ... [Read]
GWPH Stock Recovers on Regained Sativex Rights
GWPH stock is bouncing back from losses incurred earlier this month in light of missed earnings after GW Pharmaceuticals (NASDAQ:GWPH) announced that it had regained the rights to commercialize the cannabis-based medicine Sativex in the ... [Read]
GWPH Stock Tanks Despite Solid Q4 Earnings, Epidiolex Drug Sales Jump
GWPH stock is trading lower on Wednesday despite GW Pharmaceuticals (NASDAQ:GWPH) reporting better-than-estimated earnings for the fourth quarter. GW Pharmaceuticals has been one of the most notable successes in the medical marijuana industry, and its ... [Read]
GWPH Stock Gains on US Application for Expanded Use of Epidiolex
GWPH stock is trading in the green this morning after GW Pharmaceuticals (NASDAQ:GWPH) filed a supplemental marketing application in the US seeking approval for Epidiolex. Key Trigger The medical cannabis space has grown at a ... [Read]
GWPH Stock Gains After Issuing Preliminary Sales Update
GWPH stock is gaining momentum on Monday after GW Pharmaceuticals (NASDAQ:GWPH) announced its preliminary unaudited product sales report for the fourth quarter. Reports $108 Million in Revenue The cannabis sector may have been in a ... [Read]
GWPH Stock Slumps Despite Solid Q3 Earnings Thanks to Epidiolex
GWPH stock is having its worst one-day fall in the past few months despite GW Pharmaceuticals (NASDAQ:GWPH) posting better-than-expected revenue from its flagship product, Epidiolex. Solid Earnings Despite the troubles of the past few months, ... [Read]
GWPH Stock Gains 3%: Epidiolex Green Lit by European Commission
GWPH stock is witnessing solid gains in early session on Monday after GW Pharmaceuticals (NASDAQ:GWPH) announced that the European regulators approved the company's CBD oil in two seizure disorders. Impressive Development The cannabis industry has ... [Read]
GWPH Stock Extends the Fall: Time to Rethink Next Move?
GWPH stock has been witnessing continuous selling pressure over the past few weeks. Let's analyze the recent developments from GW Pharmaceuticals (NASDAQ:GWPH). Recent Developments There is no doubt that the past several months of 2019 ... [Read]
Arcadia Stock Climbs 34% on Management Succession Announcement
Arcadia Biosciences (NASDAQ:RKDA) has today announced Matthew Plavan as its next CEO, boosting Arcadia stock over 34% as a result. Year-High for Arcadia Stock Plavan will replace outgoing CEO Raj Ketkar, who will retire on ... [Read]